Stockscreener 앱 받기
14.14
4.12%
0.56
시간 외 거래:
14.50
0.36
+2.55%
전일 마감가:
$13.58
열려 있는:
$13.24
하루 거래량:
1.53M
Relative Volume:
3.20
시가총액:
$973.93M
수익:
$62.71M
순이익/손실:
$-112.51M
주가수익비율:
5.05
EPS:
2.8
순현금흐름:
$-96.01M
1주 성능:
+12.40%
1개월 성능:
-2.82%
6개월 성능:
+68.13%
1년 성능:
+52.54%
1일 변동 폭
$13.11
$14.15
1주일 범위
$12.48
$14.15
52주 변동 폭
$7.97
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
명칭
Zymeworks Inc.
전화
604-678-1388
주소
1385 West 8th Avenue, Suite 540, Vancouver, BC
ZYME을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
14.14 | 973.93M | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-07 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | 재개 | Wells Fargo | Overweight |
| 2023-01-04 | 재확인 | H.C. Wainwright | Neutral |
| 2022-12-20 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | 재개 | Wells Fargo | Overweight |
| 2022-05-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-03-15 | 개시 | Evercore ISI | Outperform |
| 2021-12-10 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | 재개 | Guggenheim | Neutral |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-02-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | 재개 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-08-06 | 개시 | SVB Leerink | Outperform |
| 2020-01-10 | 개시 | Wolfe Research | Outperform |
| 2019-12-09 | 개시 | JP Morgan | Neutral |
| 2019-11-25 | 개시 | H.C. Wainwright | Buy |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-09-30 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | 개시 | Stifel | Buy |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-05-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-03-19 | 개시 | Raymond James | Outperform |
모두보기
Zymeworks Inc. 주식(ZYME)의 최신 뉴스
Zymeworks (NYSE:ZYME) Shares Down 2.4%Here's Why - MarketBeat
Y Intercept Hong Kong Ltd Has $147,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Zymeworks (NYSE:ZYME) Stock Price Up 4.3% Following Analyst Upgrade - MarketBeat
Wells Fargo & Company Issues Positive Forecast for Zymeworks (NYSE:ZYME) Stock Price - MarketBeat
Zymeworks Stock: Prime Time Ziihera, Early-Stage Pipeline Ahead Of Schedule (NASDAQ:ZYME) - Seeking Alpha
Wellington Management Group LLP Has $3.05 Million Position in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
JP Morgan Upgrades Zymeworks (ZYME) - MSN
Zymeworks (NYSE:ZYME) Shares Gap UpHere's Why - MarketBeat
Zymeworks (NYSE:ZYME) Upgraded at JPMorgan Chase & Co. - MarketBeat
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases - The Manila Times
Zymeworks speeds up cancer drug development timeline - Investing.com
Zymeworks Hosts R&D Day Highlighting Continued Clinical - GlobeNewswire
Zymeworks Accelerates Cancer Drug Pipeline, Unveils Breakthrough Autoimmune Program 18 Months Ahead of Schedule - StockTitan
Zymeworks Inc. (NYSE:ZYME) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Zymeworks adjusts non-employee director pay By Investing.com - Investing.com Canada
Zymeworks adjusts non-employee director pay - Investing.com
Jacobs Levy Equity Management Inc. Sells 129,088 Shares of Zymeworks Inc. (NYSE:ZYME) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $19.13 Million Holdings in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Zymeworks Inc. (NYSE:ZYME) is Redmile Group LLC's 6th Largest Position - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Vestal Point Capital LP Boosts Stake in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Bloom Burton Estimates Zymeworks FY2024 Earnings - MarketBeat
HC Wainwright Reaffirms Neutral Rating for Zymeworks (NYSE:ZYME) - MarketBeat
In-Depth Examination Of 9 Analyst Recommendations For Zymeworks - Benzinga
FDA approves cancer drug developed by B.C.'s Zymeworks - Head Topics
Rare milestone for Canadian biotech as Zymeworks-developed drug gets FDA approval - The Globe and Mail
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework - Benzinga
Zymeworks to Showcase Innovations at Investor Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times
Zymeworks to Present at Major Healthcare Conferences, Announces R&D Day for Pipeline Updates | ZYME Stock News - StockTitan
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for - GlobeNewswire
Zymeworks' Ziihera Wins FDA Approval: First Dual HER2 Cancer Drug Shows 52% Response Rate | ZYME Stock News - StockTitan
Leerink Partners Upgrades Zymeworks (ZYME) - MSN
Redmile Group, LLC Adjusts Stake in Zymeworks Inc - GuruFocus.com
Zymeworks stock soars to 52-week high, hits $17.29 By Investing.com - Investing.com Australia
Zymeworks stock soars to 52-week high, hits $17.29 - Investing.com India
Zymeworks (NYSE:ZYME) Stock Rating Upgraded by Leerink Partners - Defense World
FY2024 EPS Estimates for Zymeworks Lifted by Leerink Partnrs - MarketBeat
Analysts Update Their Estimates For Zymeworks BC Inc - Stocks Register
Q4 Earnings Estimate for Zymeworks Issued By Leerink Partnrs - Defense World
Zymeworks (NYSE:ZYME) Raised to Strong-Buy at Leerink Partnrs - Defense World
Leerink Partnrs Forecasts Zymeworks' Q4 Earnings (NYSE:ZYME) - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking - Simply Wall St
Zymeworks (NYSE:ZYME) Upgraded to "Strong-Buy" at Leerink Partnrs - MarketBeat
Leerink lifts Zymeworks stock target on pipeline progress By Investing.com - Investing.com Nigeria
Leerink lifts Zymeworks stock target on pipeline progress - Investing.com
Zymeworks doses first subject in Phase I trial of ZW191 for solid tumours - Clinical Trials Arena
Citigroup Increases Zymeworks (NYSE:ZYME) Price Target to $18.00 - Defense World
Zymeworks Announces First Patient Dosed in Phase 1 Clinical - GlobeNewswire
Zymeworks Launches Phase 1 Trial for ZW191 - TipRanks
Zymeworks Inc. (ZYME) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):